D

Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192

Watchlist Manager
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Watchlist
Price: 45.1 CNY -3.34% Market Closed
Market Cap: 18.7B CNY
Have any thoughts about
Dizal Jiangsu Pharmaceutical Co Ltd?
Write Note

Relative Value

The Relative Value of one Dizal Jiangsu Pharmaceutical Co Ltd stock under the Base Case scenario is 30.31 CNY. Compared to the current market price of 45.1 CNY, Dizal Jiangsu Pharmaceutical Co Ltd is Overvalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
30.31 CNY
Overvaluation 33%
Relative Value
Price
D
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
43
vs Industry
16
Median 3Y
103.6
Median 5Y
103.6
Industry
7.7
Forward
42.5
vs History
vs Industry
Median 3Y
-16.8
Median 5Y
-16.8
Industry
22.7
Forward
-19.5
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-20.5
Industry
21.6
vs History
vs Industry
Median 3Y
-25.6
Median 5Y
-25.6
Industry
25.2
vs History
5
vs Industry
4
Median 3Y
11.2
Median 5Y
11.2
Industry
2.5
vs History
43
vs Industry
12
Median 3Y
101.5
Median 5Y
101.5
Industry
7.7
Forward
41.7
vs History
43
vs Industry
9
Median 3Y
105.3
Median 5Y
105.3
Industry
9
vs History
vs Industry
Median 3Y
-15.8
Median 5Y
-15.8
Industry
4.2
Forward
-16.5
vs History
vs Industry
Median 3Y
-15.8
Median 5Y
-15.8
Industry
4.1
Forward
-15.5
vs History
vs Industry
Median 3Y
-19.8
Median 5Y
-19.8
Industry
5.7
vs History
vs Industry
Median 3Y
-18.9
Median 5Y
-18.9
Industry
3.6
vs History
21
vs Industry
11
Median 3Y
25.1
Median 5Y
25.1
Industry
4.6

Multiples Across Competitors

Competitors Multiples
Dizal Jiangsu Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
18.4B CNY 106.6 -16.9 -16.4 -16.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 38 083 264.3 -181 004.1 -219 796.6 -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 5.6 61.5 15.3 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 10.9 -241.6 24 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 4 891.9 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 849.9 -472 -514.1 -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 5.9 17.8 16.2 18
US
Seagen Inc
F:SGT
39.3B EUR 17.8 -54.6 -58.7 -53
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.5 -129.9 -104.5 -76.2
P/E Multiple
Earnings Growth
CN
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Average P/E: 208.3
Negative Multiple: -16.9
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -181 004.1 N/A
US
Abbvie Inc
NYSE:ABBV
61.5
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -241.6
42%
US
Gilead Sciences Inc
NASDAQ:GILD
891.9
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -472 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.6 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
CN
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Average EV/EBITDA: 17.2
Negative Multiple: -16.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
CN
D
Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
Average EV/EBIT: 22.5
Negative Multiple: -16.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

See Also

Discover More
Back to Top